Holen Sie sich die Stockscreener-App
5.64
5.42%
0.29
Handel nachbörslich:
5.63
-0.010
-0.18%
Ardelyx Inc Aktie (ARDX) Neueste Nachrichten
Piper Sandler Maintains a Hold Rating on Ardelyx (ARDX) - MSN
Ardelyx's post-earnings decline attributed to concerns over Ibsrela outlook - MSN
Ardelyx gains after insider purchase, LPGA marketing deal - MSN
ARDX SEC FilingsArdelyx 10-K, 10-Q, 8-K Forms - Stock Titan
ARDX stock is down pre-market after Q4 earnings miss, so why did this firm just hike price target by 80%? - MSN
Can Ardelyx Inc stock outperform in a bear market2026 Short Interest & Stepwise Trade Execution Plans - baoquankhu1.vn
ARDX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Insider Selling: Ardelyx (NASDAQ:ARDX) CEO Sells 41,666 Shares of Stock - MarketBeat
Raab, Ardelyx CEO, sells $243k in ARDX stock By Investing.com - Investing.com Canada
Raab, Ardelyx CEO, sells $243k in ARDX stock - Investing.com
Ardelyx (ARDX) CEO exercises options, sells 41,666 shares under plan - Stock Titan
Ardelyx, Inc. Opens with 8.38% Gain, Contrasting Recent Performance Trends - Markets Mojo
Ardelyx, Inc. Hits Day High with Strong 14.49% Intraday Surge - Markets Mojo
ARDX Stock Price, Quote & Chart | ARDELYX INC (NASDAQ:ARDX) - ChartMill
Will Ardelyx’s (ARDX) IBSRELA Data Shift Its Competitive Position In IBS-C Treatments? - simplywall.st
Leerink Maintains Outperform on Ardelyx, Inc (ARDX) March 12, 2026 - Meyka
Leerink Partners reiterates Ardelyx stock rating on pipeline progress - Investing.com
Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award - The Manila Times
Five kidney disease advocates honored for decades of patient support - Stock Titan
Breakout Move: How does Ardelyx Inc correlate with Nasdaq2026 Highlights & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Ardelyx Touts IBSRELA’s 73% Growth, Reaffirms $1B 2029 Goal and Details CIC Phase III Plan - MarketBeat
Ardelyx at Leerink Conference: Strategic Growth and Pipeline Focus By Investing.com - Investing.com Canada
ARDX: IBSRELA targets $1B sales by 2029, with pipeline and commercial growth fueled by strong execution - TradingView
Assessing Ardelyx (ARDX) Valuation After Recent Share Price Weakness - Yahoo Finance
Ardelyx (ARDX) Valuation Check After Recent Share Price Weakness And Growth Expectations - simplywall.st
Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C - The Manila Times
Ardelyx, Inc. Publishes Data Supporting Tenapanor's Rapid and Sustained Relief for IBS-C in Peer-Reviewed Journal - Quiver Quantitative
Ardelyx Announces Publication of a Review Article - GlobeNewswire
Is Ardelyx (ARDX) Pricing In Its Potential After Recent Share Price Weakness - Yahoo Finance
Is Ardelyx (ARDX) Pricing Reflect Its DCF Upside After Recent Share Price Volatility - simplywall.st
Is Ardelyx Inc. (41X) stock bottoming after sell off2026 Buyback Activity & Technical Pattern Based Buy Signals - Naître et grandir
Ardelyx, Inc. (NASDAQ:ARDX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Is Ardelyx’s 2026 IBSRELA Outlook Altering The Investment Case For Ardelyx (ARDX)? - Sahm
Vanguard Group Inc. Boosts Holdings in Ardelyx, Inc. $ARDX - MarketBeat
Ardelyx to Participate in Upcoming Investor Conferences - GlobeNewswire
ARDX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Ardelyx (NASDAQ:ARDX) Stock Passes Below 200-Day Moving AverageWhat's Next? - MarketBeat
Ardelyx LPGA Partnership Puts Spotlight On Women’s Digestive Health And Growth - simplywall.st
Assessing Ardelyx (ARDX) Valuation After Strong 2025 Results And 2026 Growth Guidance - simplywall.st
Ardelyx CEO Sells 41k Shares as Company Announces Huge Partnership - The Globe and Mail
Revisiting ArdelyxInsider Weekends (NASDAQ:ARDX) - Seeking Alpha
ARDX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Ardelyx, Inc. (ARDX) Investor Outlook: Analysts See A Potential 142% Upside - DirectorsTalk Interviews
Ardelyx goes full swing with the LPGA for IBS-C awareness - Medical Marketing and Media
ARDELYX (NASDAQ: ARDX) CEO Raab sells 41,666 shares after option exercise - Stock Titan
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):